Another Step Towards Myeloma Market Dominance For Amgen's Kyprolis

Amgen Inc.'s Kyprolis (carfilzomib) has been given the green light in Europe for the treatment of relapsed multiple myeloma, after being pushed through reviews under the European Medicines Agency's accelerated assessment program.